- Home
- LUCY vs COCP Comparison
LUCY vs COCP Comparison
Compare LUCY & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- COCP
- Stock Information
- Founded
- LUCY 2017
- COCP N/A
- Country
- LUCY United States
- COCP United States
- Employees
- LUCY N/A
- COCP N/A
- Industry
- LUCY Ophthalmic Goods
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- LUCY Health Care
- COCP Health Care
- Exchange
- LUCY Nasdaq
- COCP Nasdaq
- Market Cap
- LUCY 18.5M
- COCP 18.3M
- IPO Year
- LUCY 2022
- COCP N/A
- Fundamental
- Price
- LUCY $6.85
- COCP $2.15
- Analyst Decision
- LUCY Strong Buy
- COCP Strong Buy
- Analyst Count
- LUCY 1
- COCP 1
- Target Price
- LUCY $20.00
- COCP $7.00
- AVG Volume (30 Days)
- LUCY 695.0K
- COCP 22.2K
- Earning Date
- LUCY 11-12-2024
- COCP 11-13-2024
- Dividend Yield
- LUCY N/A
- COCP N/A
- EPS Growth
- LUCY N/A
- COCP N/A
- EPS
- LUCY N/A
- COCP N/A
- Revenue
- LUCY $1,561,506.00
- COCP N/A
- Revenue This Year
- LUCY $245.17
- COCP N/A
- Revenue Next Year
- LUCY $258.97
- COCP N/A
- P/E Ratio
- LUCY N/A
- COCP N/A
- Revenue Growth
- LUCY 158.62
- COCP N/A
- 52 Week Low
- LUCY $3.26
- COCP $1.33
- 52 Week High
- LUCY $27.20
- COCP $3.10
- Technical
- Relative Strength Index (RSI)
- LUCY 46.42
- COCP 64.04
- Support Level
- LUCY $6.59
- COCP $1.65
- Resistance Level
- LUCY $8.80
- COCP $1.82
- Average True Range (ATR)
- LUCY 0.85
- COCP 0.17
- MACD
- LUCY -0.09
- COCP 0.03
- Stochastic Oscillator
- LUCY 6.82
- COCP 64.10
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products Lucyd Lyte glasses enable the wearer to listen to music, take and make calls, and use voice assistants to perform many common smartphone tasks hands free.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).